Print

Sanofi (France) (SAN.PA) MS Drug Beats Avonex in Head-to-Head  
11/1/2012 6:15:21 AM

Genzyme, now a Cambridge unit of French drug maker Sanofi SA, announced the publication of encouraging results from its studies of Lemtrada, its drug candidate for multiple sclerosis.

Results were published in the online edition of the medical journal Lancet. Lemtrada is currently being reviewed by European regulators, and at some point, Genzyme plans to submit a drug application for Lemtrada to the US Food and Drug Administration.